The biosimilars market is expected to reach USD
41.7 billion by 2024, according to a new report by Grand View Research, Inc.
The global biosimilars market is anticipated to witness a marked growth during
the period of 2016 to 2024. The most significant factor leading to the growth
of this industry is the fact that major biological drugs are nearing the patent
cliff. Further, the lower cost of these drugs as compared to the patented
biologics, the increasing encumbrance to cut down healthcare costs across the
medical systems in the world, and the favorable clinical outcomes demonstrated
through clinical trials for the biosimilar drugs is expected to boost the
industry.
For the
purpose of this study, the major countries considered are the U.S., Canada, the
UK, Germany, India, China, Brazil, and Russia. It was estimated that in 2015,
Europe accounted for the largest market share of the global biosimilars market,
followed by Asia Pacific.
The industry
is segmented on the basis of type of products and applications. With regard to
the product type, the recombinant non-glycosylated segment is projected to flourish
rapidly during the study period. On the other hand, the recombinant
glycosylated proteins segment is estimated to grow at a significant CAGR during
the period 2015 to 2024 due to the increasing, wide spread incidence of cancer
cases (24 million by 2035), which is identified as the crucial factor driving
the growth of this sector.
To request a
sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
- North America is anticipated to be the fastest growing market during the forecast period. The biosimilars market has gained significant momentum in the U.S., presenting new opportunities for R&D and the manufacturing sector of biosimilars.
- The European market is the most advanced one as it has been the first to formulate a regulatory pathway and adopt the use of biosimilars for more than 8 years now. Germany accounts for the maximum share in the biosimilars industry, followed by the rest of the European countries (UK, France, Spain, and Italy).
- The Asia Pacific market is expected to witness a lucrative growth during the period 2015 to 2024. India and China are the key countries identified that are expected to lead the industry growth in the study period.
- The market for oncology is estimated to soar at a rapid pace in accordance with the increasing incidence of cancer cases in the world. Additionally, the demand for cost-effective cancer treatments is expected to further fuel the industry growth.
- The biosimilars market comprises several local as well as global players. Some major players of this market include Amgen, Inc., Beacon Ltd., Tea Pharmaceutical Industries Ltd., Merck & Co., Milan, Inc., Dr. Reddy’s Laboratories, Inc., Sandoz, Inc., and Celltrion Healthcare Co., Ltd.
See More Reports of This Category:
About
Grand View Research:
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
No comments:
Post a Comment